Chordoma

Modern Study Review (AI-Generated)

High-Yield Summary

Chordoma is a rare, slow-growing malignant tumor arising from notochordal remnants, predominantly located in the sacrococcygeal region and clival (skull base) area. It typically presents in middle-aged adults with insidious pain and neurological symptoms due to local mass effect. Diagnosis relies on imaging and histopathology, with treatment centered on aggressive surgical resection and adjuvant radiotherapy for unresectable disease. Prognosis is guarded due to local recurrence and potential for distant metastases.

Key Diagnostic Findings

Anatomy

• Originates from primitive notochord remnants along the axial skeleton.
• Most common sites: sacrum (>50%), clivus/skull base, and mobile spine.
• Tumor grows along the midline, often involving adjacent neural and visceral structures.

Clinical Presentation

• Pain: Gradual onset, often chronic and localized to the tumor site.
• Mass effect symptoms: Large presacral mass may cause rectal fullness or palpable mass.
• Neurological deficits: Bowel and bladder dysfunction due to sacral nerve root involvement.
• Symptoms often present late due to slow tumor growth.

Imaging

• X-rays: Destructive, lytic bony lesion with an expansile soft tissue mass.
• MRI: Best modality; shows lobulated, T2 hyperintense mass with heterogeneous enhancement.
• CT: Useful for assessing bony destruction and surgical planning.

Histology

• Characteristic physaliphorous cells: large polyhedral cells with vacuolated eosinophilic cytoplasm displacing the nucleus.
• Cells arranged in cords, trabeculae, or sheets within abundant myxoid and mucoid matrix.
• Immunohistochemistry: Positive for brachyury (a key diagnostic marker).

Classification Systems

• No widely used formal staging system specific to chordoma; however, tumor size, location, and extent of local invasion guide prognosis and treatment planning.

Current Gold Standard Treatment

– Surgical goal: Achieve wide margins to reduce local recurrence risk.

• Adjuvant therapy: Radiotherapy is used postoperatively for positive margins or unresectable disease.
• Multidisciplinary approach: Neurosurgery, orthopaedics, radiation oncology collaboration essential.

Modern Complications & Outcomes

Complications

• Local recurrence: High rate (up to 50%) due to difficulty achieving wide margins.
• Neurological deficits: Sacral nerve root sacrifice can cause bowel, bladder, and sexual dysfunction.
• Metastases: Occur in 20-40% of cases, commonly to lungs, liver, bone, and lymph nodes.
• Radiation toxicity: Potential damage to adjacent neural and visceral structures.

Outcomes

• 5-year survival ranges from 50-70%, depending on tumor location and completeness of resection.
• Prognosis worsens with incomplete resection, metastases, and clival location.
• Long-term follow-up is mandatory due to late recurrences.

Classic Clinical Notes

Chordoma

• Arises from remnants of primitive notochord found in midline at either end of the spine (sacrum > sphenooccipital region) in middle-aged men.

Signs & Symptoms:

• Gradual onset of pain & usually long duration prior to diagnosis.
• Large presacral rectal mass.
• Bowel or bladder dysfunction.

X-rays:

• Destructive bony lesion associated with an expansile soft tissue mass.

Histology:

• Polyhedral cells with eosinophilic cytoplasm & many vacuoles which displace the nucleus = physaliphorous cells.
• Cells disposed in cords, trabeculae or sheets which are separated by abundant mucoid & myxoid matrix.

Treatment:

• Wide excision (may have to sacrifice sacral roots).
• Radiation if not resectable.
• Frequent metastases to lungs, liver & other tissues.

Last Updated on January 25, 2026 by orthonet